Clinical trials: Operable Breast Neoplasms
Primary Breast Cancer
Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
The primary objective of this trial is to compare the rate of pathologically complete remissions achieved using a preoperative dose-intensified 8 week therapy consisting of adriamycin and docetaxel with a preoperative sequential…
- Trial name
- NCT00793377
- Testing
- Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
- Where
- Germany
- Volunteers
- 913 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells and shrink tumors so they can be removed during…
- Trial name
- NCT00008034
- Testing
- capecitabine, cyclophosphamide, epirubicin hydrochloride
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer
The primary objective of this study is to compare disease-free survival (DFS) of patients with operable breast cancer randomised to treatment with standard adjuvant chemotherapy plus moxifloxacin or placebo.
- Trial name
- NCT05114720
- Testing
- standard adjuvant chemotherapy plus moxifloxacin
- Where
- China
- Volunteers
- 559 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
This single arm study will assess the efficacy and safety of a combination of Avastin and docetaxel following cyclophosphamide and doxorubicin, in patients with HER2 negative operable breast cancer.
- Trial name
- NCT00559754
- Testing
- bevacizumab [Avastin], Docetaxel, Standard chemotherapy
- Where
- 6 sites in Spain
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients
This is a prospective, open-label, randomized, phase III trial. Patients will be stratified after breast surgery, as per investigational site; menopausal status; node negative diagnosis, as per sentinel-node technique versus…
- Trial name
- NCT00129389
- Testing
- Fluorouracil, Doxorubicin, Cyclophosphamide
- Where
- 68 sites in Spain
- Volunteers
- 1,925 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer
Select patients of primary breast cancer whose hormone receptor is positive and accepted postoperative adjuvant aromatase inhibitors for endocrine treatment.Treat them with zoledronic acid 4mg intravenous infusion every six…
- Trial name
- esozao (NCT01654367)
- Testing
- Zoledronic Acid and Aromatase Inhibitors
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
RBX7455 Before Surgery for the Treatment of Operable Breast Cancer
This clinical trial studies the side effects and possible benefits of RBX7455 given before surgery in treating patients with breast cancer that can be removed by surgery (operable).
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04139993
- Testing
- Microbiota-based Formulation RBX7455
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Tubular Breast Cancer, Mucinous Breast Cancer
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
The investigators hypothesize that paclitaxel combined with cisplatin in a weekly-based regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast cancer.
- Conditions
- Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer
- Trial name
- SHPD002 (NCT02221999)
- Testing
- Paclitaxel, Cisplatin, Gonadotropin-releasing hormone agonist
- Where
- 12 sites in China
- Volunteers
- 250 people
- Sponsor
- RenJi Hospital
Operable Breast Neoplasms
Correlation of Predictive Accuracy of PREDICT Version 2.2 of Indian Women With Operable Breast Cancer
This is an observational retrospective study which aims at comparing the 5-year survival estimates from "PREDICT V2.2" with observed 5-year outcome from our dataset of Indian women treated for operable breast cancer.
- Trial name
- PREDICT (NCT04985253)
- Testing
- prediction of overall survival using Web based PREDICTV2.0 portal
- Where
- India
- Volunteers
- 2,780 people
- Sponsor
- Tata Memorial Centre
Breast Cancer
Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast Cancer
EFFICACY OF NEOADJUVANT ENDOCRINE THERAPY WITH ANASTROZOLE IN POMENOPAUSAL WOMEN WITH ER-POSITIVE BREAST CANCER. Flavia Morales-Vásquez, Horacio Noé López Basave.
- Trial name
- NCT00437853
- Testing
- Anastrozole
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Breast Cancer
Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer
Background: Taxane plays a key role in the treatment of breast cancer and taxane-induced peripheral neuropathy (TIPN) is a dose-limiting adverse effect leading to treatment discontinuation.
- Trial name
- NCT02468739
- Testing
- Ganglioside-monosialic acid
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-sen University
Adenocarcinoma
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at…
- Trial name
- NCT00140075
- Testing
- Epirubicin with Cyclophosphamide, followed by a Taxane, Epirubicin with a Taxane
- Where
- 54 sites in United States
- Volunteers
- 606 people
- Sponsor
- Pfizer
Breast Cancer
Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00096343
- Testing
- carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Alabama at Birmingham
Neoadjuvant Operable Breast Cancer
Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women
The investigators propose in the present study an innovative approach, combining the most recent therapeutic opportunities in high risk ER+ breast cancer with the most recent and innovative diagnostic approaches such as the PAM50…
- Trial name
- NeoPAL (NCT02400567)
- Testing
- Fluorouracile, Epirubicin, Cyclophosphamide
- Where
- 2 sites in France
- Volunteers
- 125 people
- Sponsor
- UNICANCER
Breast Cancer
Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery
RATIONALE: Metformin hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying how well metformin hydrochloride works in treating women with…
- Trial name
- NCT00984490
- Testing
- metformin hydrochloride, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer, Cognitive/Functional Effects
Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Depression, Malnutrition
- Trial name
- NCT00424203
- Testing
- AC regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 17 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Breast Cancer
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and paclitaxel (albumin-stablized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00397761
- Testing
- capecitabine, paclitaxel albumin-stabilized nanoparticle formulation, neoadjuvant therapy
- Where
- United States
- Sponsor
- Medstar Health Research Institute
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
RATIONALE: Studying how older women make treatment decisions and how these decisions affect the outcome of treatment may help doctors plan more effective treatments and improve patient quality of life.
- Trial name
- NCT00068328
- Testing
- psychosocial assessment and care, quality-of-life assessment
- Where
- 85 sites in United States
- Volunteers
- 1,706 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Trial to optimize neoadjuvant therapy for HER overexpression and co-expressing of hormone receptors(ER and/or PR) breast cancer (HEr2+/HR+).
- Trial name
- ADAPT; T-DM1 (NCT01745965)
- Testing
- T-DM1, Trastuzumab
- Where
- 2 sites in Germany
- Volunteers
- 380 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer
Clinical Application of CTDNA in Operable Breast Cancer Patients
Our study aims to evaluate the possibility of clinical application of CTDNA detection in samples or peripheral blood of breast cancer patients, so as to act as the new techniques or indicators of early diagnosis, therapy…
- Trial name
- NCT02797652
- Testing
- Neoadjuvant chemotherapy before surgery, Surgery followed by adjuvant chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital